Q07820 (MCL1_HUMAN) Homo sapiens (Human)

Induced myeloid leukemia cell differentiation protein Mcl-1 UniProtKBInterProSTRINGInteractive Modelling

350 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

129 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Solution Structure of human Mcl-1 complexed with human Bid_BH3 peptide Heteromer
P55957;
167-326
100
Mcl-1 in complex with Bim BH3 mutant I2dY Heteromer
O43521;
172-326
100TRS;
Mcl-1 complexed with Mule Heteromer
Q7Z6Z7;
171-325
100
Human Mcl-1 in complex with a modified Bim BH3 peptide Heteromer
O43521;
172-325
100
Human Mcl-1 in complex with a modified unnatural Bim BH3 peptide Heteromer
O43521;
172-325
100ADM;
Human Mcl-1 in complex with a Bfl-1-specific selected peptide Heteromer
172-325
100ZN;SO4;
Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design Heteromer
172-324
100
Human Mcl-1 in complex with the designed peptide dM1 Heteromer
172-324
100ZN;
Human Mcl-1 in complex with the designed peptide dM7 Heteromer
172-323
100CL;
Mcl-1 in complex with Bim BH3 mutant I2dA Heteromer
O43521;
172-322
100ZN;ACT;CL;
Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival proteiā€¦ Heteromer
Q96LC9;
171-321
100.0
Structure of human Mcl-1 in complex with PUMA BH3 peptide Heteromer
Q9BXH1;
171-321
93.62ZN;CL;
Mcl1 in complex with a Fab Heteromer
174-324
94.7
MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 29 Heteromer
P97287;
172-322
1007LT;
Crystal structure of MCL-1 in complex with a neutralizing Alphabody CMPX-383B Heteromer
172-322
100.0ZN;
Mcl-1 in complex with Bim BH3 mutant F4aE Heteromer
O43521;
172-322
100ZN;ACT;
Structure of human Mcl-1 in complex with BIM BH3 peptide Heteromer
O43521;
172-322
100.0ZN;
BimL12Y in complex with Mcl-1 Heteromer
O43521; P97287;
172-322
100ZN;
Crystal structure of Mcl1-inhibitor complex Heteromer
172-322
100
Crystal structure of human Mcl-1 in complex with modified Bim BH3 peptide SAH-MS1-18 Heteromer
172-321
100.0ZN;
Crystal structure of Mcl-1 bound to BID-MM Heteromer
P55957;
173-322
100GOL;
X-ray crystal structure of human Mcl-1 in complex with Bim BH3 Heteromer
172-321
100.0ZN;NA;
Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs Heteromer
173-322
100.0
MCL-1 complex with MCL-1-specific selected peptide Heteromer
172-321
100.0ZN;SO4;
Crystal structure of MCL-1 in complex with computationally designed inhibitor protein Heteromer
172-321
100
Crystal structure of human Mcl-1 in complex with modified Bim BH3 peptide SAH-MS1-14 Heteromer
172-320
100ZN;
Crystal structure of Mcl-1 in complex with 138E12 peptide, Lys-covalent antagonist Heteromer
O43521;
173-321
100.0
INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN FABCOMPLEX IN COMPLEX WITH COMPOUND 1 Heteromer
174-322
94.63VF8;
Apo Mcl1 in a complex with a scFv Heteromer
174-321
97.14
Structure of an anti-Mcl1 scFv Heteromer
174-321
97.14DMS;
INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN FABCOMPLEX IN COMPLEX WITH AZD5991 Heteromer
174-321
94.59E4W;
Mcl1-scFv complex with an indole acid inhibitor Heteromer
174-321
97.14HVN;
Crystal structure of Mcl-1 in complex with the BaxBH3 domain Heteromer
Q07812;
174-321
100.010×CD;
Crystal structure of the Mcl-1:Bim BH3 complex Heteromer
O43521; P97287;
241-322
100ZN;CL;
Mcl-1 bound to alpha beta Puma BH3 peptide 3 Heteromer
P97287; Q9BXH1;
241-322
10010×ZN;CL;
Mcl-1 in complex with Bim-h3Pc-RT Heteromer
O43521; P97287;
241-322
100EDO;
Mcl-1 bound to alpha beta Puma BH3 peptide 2 Heteromer
P97287; Q9BXH1;
241-322
10010×CD;
Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand Heteromer
O43521; P97287;
241-322
100ZN;
MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 21 Heteromer
P97287;
241-322
1007LW;
Crystal structure of the Mcl-1:mNoxaB BH3 complex Heteromer
P97287; Q9JM54;
241-321
100
Crystal structure of ARC4 from human Tankyrase 2 in complex with peptide from human MCL1 Heteromer
Q9H2K2;
76-88
92.31
Crystal structure of MCL-1 in complex with a BIM competitive inhibitorhomo-2-mer174-322
100.09EA; 10×ZN;
The MCL-1 BH3 Helix is an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizerhomo-2-mer172-320
100.0
NMR Structure of human Mcl-1monomer171-327
99.36
hMcl1 inhibitor complexmonomer171-327
99.36N8J;
Crystal structure of Mcl1 with inhibitor 8monomer171-326
100N0M;
X-ray co-crystal structure of compound 8 bound to human Mcl-1monomer171-326
100Q4Y;
X-ray co-crystal structure of compound 3 bound to human Mcl-1monomer172-326
100Q51;
X-ray co-crystal structure of compound 10 bound to human Mcl-1monomer172-326
100Q4V;
Co-crystal structure of Mcl1 with inhibitor 10monomer172-326
100N0J;
co-crystal structure of compound 1 bound to human Mcl-1monomer172-326
100Q4D;
X-ray co-crystal structure of compound 20 with Mcl-1monomer172-326
100Q4S;
Mcl-1 complexed with small molecule inhibitormonomer172-325
1005X3;
Histidine-covalent stapled alpha-helical peptide (155H1) targeting hMcl-1monomer172-323
100A1AJE;A1AJD;
Crystal structure of Mcl1 with inhibitor 9monomer171-322
100N0S;
Crystal structure of MCL-1 in complex with a BIM competitive inhibitormonomer174-325
100CN7;
Structure of Mcl-1 in complex with compound 10dmonomer171-322
100JL8;
Crystal structure of Mcl-1 in complex with compound 10monomer172-323
100LC6;
Mcl-1 complexed with small moleculesmonomer172-323
1004M7;
MCL1 in complex with indole acid ligandmonomer174-325
95.33E4K;
Crystal structure of Mcl1 with inhibitor 7monomer171-321
100N0P;
X-ray co-crystal structure of compound 7 with Mcl-1monomer171-321
100Q57;
X-ray co-crystal structure of compound 5 with Mcl-1monomer171-321
100Q54;
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors that Demonstrate in vivo Activity inā€¦monomer172-322
100KJP;
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Designmonomer172-322
1006AK;
Mcl-1 complexed with small moleculesmonomer172-322
1004M6;
The crystal structure of anti-apoptotic Mcl-1 protein in complex with 2, 5-substituted benzoic acidā€¦monomer171-321
100PZY;
The crystal structure of human mcl1 kinase domain in complex with MCL1-M-EBAmonomer172-321
100.0QHR;
Co-crystal structure of Mcl1 with inhibitormonomer172-321
100LOD;
Structure of human Mcl-1 in complex with indole acid inhibitormonomer172-321
100J3E;
Crystal structure of Mcl-1 in complex with compound 65monomer171-320
99.33NQJ;
Co-crystal structure of Mcl1 with inhibitormonomer172-321
100.0LMV;
Mcl-1 bound to compound 24monomer172-321
100Q01;BNL;
Structure of Mcl-1 in complex with compound 8bmonomer171-320
100JLE;
Structure of Mcl-1 complex with compound 1monomer171-320
100U6Q;MG;PG6;
Crystal structure of Mcl-1 in complex with compound 4monomer172-321
100LC3;
Structure of Mcl-1 in complex with compound 8dmonomer171-320
100JLK;
Structure of Mcl-1 in complex with compound 8amonomer171-320
100JLE;
Mcl-1 bound to compound 19monomer172-321
100Q0A;EDO;
Structure of Mcl-1 in complex with compound 13monomer171-320
100JL5;
Co-crystal structure of Mcl1 with inhibitormonomer172-321
100.0LOJ;
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Designmonomer172-321
1006AL;
Mcl-1 complexed with small moleculesmonomer172-321
100ECY;
Mcl-1 bound to compound 17monomer172-321
100.0Q0D;
Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based designmonomer172-321
100.019H;PGE;
Structure of Mcl-1 complex with compound 6bmonomer171-320
100U6N;
MBP-Mcl1 in complex with ligand 11monomer173-321
97.99GLC;FMT;YLT;
MBP-Mcl1 in complex with ligand 32monomer173-321
97.99GLC; 10×EDO;YLF;
MBP-Mcl1 in complex with ligand 10monomer173-321
97.99GLC;EDO;GOL;WUC;
Mcl-1 complexed with small molecule inhibitormonomer172-320
97.125WL;5WK;
MBP-Mcl1 in complex with ligand 34monomer173-321
97.99GLC;CL;EDO;PEG;YKL;
STRUCTURE OF MCL1 BOUND TO BRD inhibitor ligand 1 AT 1.7Amonomer173-321
100ZN;865;POP;
MBP-Mcl1 in complex with ligand 28monomer173-321
97.99GLC;EDO;PEG;YKX;
Structure of human Mcl-1 in complex with thienopyrimidine inhibitormonomer173-321
98.64GLC;J1N;NA;
MBP-Mcl1 in complex with ligand 12monomer173-321
97.99GLC;FMT;EDO;YLK;
A Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)monomer173-321
97.97GLC;3M6;MG; 10×FMT;
MBP-Mcl1 in complex with ligand 21monomer173-321
97.99GLC;EDO;YKT;
Structure of MBP-Mcl-1 in complex with compound 4dmonomer173-321
97.99GLC;CL;OK2;
Structure of Mcl-1 in complex with compound 2gmonomer172-320
100.0OJT;CL;
Structure of MBP-Mcl-1 in complex with compound 18amonomer173-321
98.64GLC;JLH;
Structure of MBP-Mcl-1 in complex with compound 9mmonomer173-321
97.99GLC;OK5;
Crystal structure of human Mcl-1 in complex with compound 1monomer173-321
97.99GLC;WXW;
Structure of MBP-Mcl-1 in complex with compound 8bmonomer173-321
97.99GLC;JLE;NA;
Crystal structure of the MBP-MCL1 complex with highly selective and potent inhibitor of MCL1monomer173-321
97.99GLC;70R;
Structure of MBP-Mcl-1 in complex with compound 8amonomer173-321
97.99GLC;JLE;NA;
Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based designmonomer172-320
10019G;
Structure of MBP-Mcl-1 in complex with compound 10dmonomer173-321
97.99GLC;JL8;
Structure of MBP-Mcl-1 in complex with compound 3emonomer173-321
97.99GLC;CL;OJW;
Mcl-1 bound to compound 17monomer172-320
100.0Q0G;
Mcl-1 complexed with small molecule inhibitormonomer172-320
100.05X2;
Crystal Structure of Human MCL-1 Bound to Inhibitor 4-(4-methylnaphthalen-1-yl)-2-{[(4-phenoxyphenyā€¦monomer174-322
100.02UU;
Mcl-1 complexed with small moleculesmonomer172-320
100ECM;
Structure of MBP-Mcl-1 in complex with MIK665monomer173-320
97.97GLC;OK5;
Crystal structure of human MBP-Myeloid cell leukemia 1 (Mcl-1) in complex with BRD810 inhibitormonomer174-321
97.97GLC;MG;YI7;DMS;PGE;
MCL1 in complex with an indole acid ligandmonomer174-321
94.59E4Q;
Structure of MBP-Mcl-1 in complex with compound 6amonomer173-320
97.97GLC;JKQ;NA;
Myeloid cell leukemia-1 (Mcl-1) complexed with compoundmonomer173-320
97.97GLC;A1ALT;
The structure of MBP-MCL1 bound to ligand 5 at 1.9Amonomer174-321
97.97GLC;MG;EDO;FMT;3R6;
Structure of MBP-Mcl-1 in complex with a macrocyclic compoundmonomer173-320
97.97GLC;WLW;
The structure of MBP-MCL1 bound to ligand 6 at 2.0Amonomer174-321
97.97GLC;3R7; 10×FMT;MG;
Structure of MBP-Mcl-1 in complex with compound 7amonomer173-320
97.97GLC;JLB;
STRUCTURE OF MBP-MCL1 BOUND TO ligand 4 AT 2.4Amonomer174-321
97.97GLC;CL;MG;3R4;
Structure of MBP-Mcl-1 in complex with ABBV-467monomer173-320
97.97GLC;WME;
STRUCTURE OF MBP-MCL1 BOUND TO ligand 2 AT 1.55Amonomer174-320
97.96GLC;19H;MG; 13×FMT;NA;EDO;
Crystal Structure of Human MCL-1 Bound to Inhibitor 4-hydroxy-4'-propylbiphenyl-3-carboxylic acidmonomer174-320
100.02UV;
STRUCTURE OF APO MBP-MCL1 AT 1.9Amonomer174-320
97.92GLC;MG;EDO; 10×FMT;
Crystal structure of MCL-1 in complex with a BIM competitive inhibitormonomer174-320
100CJY;
STRUCTURE OF MBP-MCL1 BOUND TO ligand 1 AT 2.35Amonomer174-320
97.96GLC;865;EDO; 11×FMT;
Crystal structure of MCL1 with compound 1monomer241-322
100NA;6XJ;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5jsb.1.Amonomer0.81172-322
100.00

1 SWISS-MODEL model built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 25c6h.1.Mmonomer0.59171-235
92.31